34,597 results match your criteria Graft Versus Host Disease


Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease (GVHD).

Transplant Cell Ther 2021 Jun 9. Epub 2021 Jun 9.

Bone Marrow Transplant, Hospital Sirio Libanes, São Paulo, Brazil; Division of Hematology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.

Chronic graft-versus-host disease (cGVHD) remains a major barrier to a successful hematopoietic stem cell transplantation (HSCT); in cases refractory to first-line therapy with steroids, there is no standard of care for second-line therapy. As such, ruxolitinib is a promising drug in this scenario. We retrospectively analyzed its efficacy and safety as treatment of steroid-refractory cGVHD in 35 patients from two transplant centers, with the longest follow-up described to date. Read More

View Article and Full-Text PDF

Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: γδ T cells and MRD+ AML.

Transplant Cell Ther 2021 Jun 9. Epub 2021 Jun 9.

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:

Background: Minimal residual disease (MRD) prior to allogeneic stem cell transplantation (allo-SCT) in AML is a poor risk factor for outcome. The γδ T cells represents a unique minority lymphocyte population which is preferentially located in peripheral tissues, can recognize antigens in non-MHC restricted manner and plays a "bridging" role between innate and adaptive immune system.

Objectives: In this study, we investigated a potential graft-vs-leukaemia effect of γδ T cells reconstitution post-transplant in AML patients with pre-transplant positive minimal/measurable disease status (MRD+). Read More

View Article and Full-Text PDF

Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation.

Int J Lab Hematol 2021 Jun 12. Epub 2021 Jun 12.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Introduction: The appearance of erythroblasts (EBLs) in peripheral blood occurs in a variety of serious conditions and has been associated with mortality in critically ill patients. However, the incidence, risk factor, and outcomes of EBLs after cord blood transplantation (CBT) remain unclear.

Methods: We have investigated the impact of EBLs on transplant outcomes on 225 adult patients who underwent single-unit CBT at our single institute. Read More

View Article and Full-Text PDF

Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen.

Int J Hematol 2021 Jun 12. Epub 2021 Jun 12.

Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Hefei, China.

Objective: To explore the incidence and risk factors of late-onset hemorrhagic cystitis (LOHC) in patients undergoing single umbilical cord blood transplantation for hematological malignancies.

Methods: Clinical data from 234 patients who consecutively underwent single UCBT using a myeloablative conditioning regimen without antithymocyte globulin in our center were retrospectively analyzed.

Results: In total, 64 (27. Read More

View Article and Full-Text PDF

Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells Autologous B Cells.

Front Immunol 2021 25;12:658562. Epub 2021 May 25.

Department of Cancer Center, The First Hospital of Jilin University, Changchun, China.

Natural killer (NK) cells are becoming valuable tools for cancer therapy because of their cytotoxicity against tumor cells without prior sensitization and their involvement in graft-versus-host disease; however, it is difficult to obtain highly cytotoxic NK cells without adding extra feeder cells. In this study, we developed a new method for obtaining highly cytotoxic NK cells from peripheral blood mononuclear cells (PBMCs) independently of extra feeder cell addition using rituximab not coated on a flask (non-coated rituximab). We found that rituximab could promote both the activation and expansion of NK cells from PBMCs, irrespective of being coated on a flask or not. Read More

View Article and Full-Text PDF

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.

J Immunother Cancer 2021 Jun;9(6)

St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, England, UK

Background: Cancer immunotherapy with monoclonal antibodies and chimeric antigen receptor (CAR) T cell therapies can benefit from selection of new targets with high levels of tumor specificity and from early assessments of efficacy and safety to derisk potential therapies.

Methods: Employing mass spectrometry, bioinformatics, immuno-mass spectrometry and CRISPR/Cas9 we identified the target of the tumor-specific SF-25 antibody. We engineered IgE and CAR T cell immunotherapies derived from the SF-25 clone and evaluated potential for cancer therapy. Read More

View Article and Full-Text PDF

Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells.

Immunohorizons 2021 Jun 10;5(6):424-437. Epub 2021 Jun 10.

Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Graft-versus-host disease (GVHD) remains to be a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). IL-2-inducible T cell kinase (ITK), a TEC cytoplasmic tyrosine kinase, has an essential role in T cell development and receptor signaling. The ITK/Bruton tyrosine kinase inhibitor ibrutinib has been shown to improve chronic GVHD symptoms; however, the effect of ITK selective inhibition on acute GVHD remains unclear. Read More

View Article and Full-Text PDF

Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series.

Pediatr Rheumatol Online J 2021 Jun 10;19(1):87. Epub 2021 Jun 10.

Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, 90095, USA.

Background: With the advent of innovative therapies including biologics and Janus kinase inhibitors, children with rheumatic diseases are more likely to have improved outcomes. Despite these advances, some children do not respond, or they, or their parents fear adverse events and seek other alternatives. Increasingly, private companies are offering mesenchymal stem cells (MSC) as an alternative, which are described as natural therapies for rheumatic diseases, often insinuating them as a cure. Read More

View Article and Full-Text PDF

Malignant transformation of oral lichen planus: a retrospective study of 565 Japanese patients.

BMC Oral Health 2021 Jun 10;21(1):298. Epub 2021 Jun 10.

Department of Oral and Maxillofacial Surgery, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Background: Oral lichen planus (OLP) is a chronic inflammatory oral mucosa disease that is recognized as an oral potentially malignant disorder. However, the potentially malignant nature of OLP remains unclear.

Methods: We designed this study to examine the demographic and clinical characteristics of patients with OLP and evaluate the associated malignant transformation rate. Read More

View Article and Full-Text PDF

Infection related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: An Australian registry report.

Transplant Cell Ther 2021 Jun 7. Epub 2021 Jun 7.

National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

Background: Infection related mortality (IRM) is the most common non-relapse mortality reported post allogeneic hematopoietic cell transplantation (HCT). Information on the incidence and timing of specific infective organisms and the risk factors for IRM is essential to developing prevention strategies.

Objective: This report provides the first account of IRM in adults and children undergoing HCT in Australia. Read More

View Article and Full-Text PDF

A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.

Bone Marrow Transplant 2021 Jun 9. Epub 2021 Jun 9.

Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, USA.

Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there are no approved treatments for SR aGvHD. Vedolizumab is approved for treatment of ulcerative colitis and Crohn's disease, and may be effective for treatment of SR intestinal aGvHD. Read More

View Article and Full-Text PDF

IL-7 and IL-15 Levels Reflect the Degree of T Cell Depletion during Lymphopenia and Are Associated with an Expansion of Effector Memory T Cells after Pediatric Hematopoietic Stem Cell Transplantation.

J Immunol 2021 Jun 9. Epub 2021 Jun 9.

Hematopoietic Stem Cell Transplantation and Primary Immune Deficiency, Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Differentially and functionally distinct T cell subsets are involved in the development of complications after allogeneic hematopoietic stem cell transplantation (HSCT), but little is known about factors regulating their recovery after HSCT. In this study, we investigated associations between immune-regulating cytokines, T cell differentiation, and clinical outcomes. We included 80 children undergoing allogeneic HSCT for acute leukemia using bone marrow or peripheral blood stem cells grafted from a matched sibling or unrelated donor. Read More

View Article and Full-Text PDF

Methods to assess disease activity and severity in cutaneous chronic graft-versus-host disease: a critical literature review.

Transplant Cell Ther 2021 Jun 6. Epub 2021 Jun 6.

Department of Dermatology, Mayo Clinic, Rochester, MN, USA. Electronic address:

Background: Chronic graft-versus-host disease (cGVHD), a potentially debilitating complication of hematopoietic cell transplantation, confers increased risk for mortality. While treatment decisions rely on an accurate assessment of disease activity/severity, validated methods of assessing cutaneous cGVHD activity/severity appear to be limited.

Objective: We aimed to identify and evaluate current data on the assessment of disease activity/severity in cutaneous cGVHD Study Design: Using modified PRISMA methods, we performed critical literature review for relevant articles. Read More

View Article and Full-Text PDF

Major pulmonary complications following Hematopoietic stem cell transplantation: What the pulmonologist needs to know.

Respir Med 2021 Jun 2;185:106493. Epub 2021 Jun 2.

Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI, 48201, USA. Electronic address:

Hematopoietic stem cell transplantation (HSCT) is used for treatment of a myriad of both malignant and non-malignant disorders. However, despite many advances over the years which have resulted in improved patient mortality, this subset of patients remains at risk for a variety of post-transplant complications. Pulmonary complications of HSCT are categorized into infectious and non-infectious and occur in up to one-third of patients undergoing HSCT. Read More

View Article and Full-Text PDF

Organ sparing total marrow irradiation compared to total body irradiation prior to allogeneic stem cell transplantation.

Eur J Haematol 2021 Jun 9. Epub 2021 Jun 9.

Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

Objectives: Total body irradiation (TBI) is commonly used prior to hematopoietic stem cell transplantation (HSCT) in myeloablative conditioning regimens. However, TBI may be replaced by total marrow irradiation (TMI) at centers with access to Helical TomoTherapy, a modality that has the advantage of delivering intensity modulated radiotherapy to long targets such as the entire bone marrow compartment. Toxicity after organ sparing TMI prior to HSCT has not previously been reported compared to TBI or with regards to engraftment data. Read More

View Article and Full-Text PDF

[Age does not affect the outcome of allogeneic hematopoietic precursor transplantation for acute myeloid leukemia].

Rev Med Chil 2021 Jan;149(1):22-29

Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. Read More

View Article and Full-Text PDF
January 2021

[Research Advance of Autophagy in Acute Intestinal Graft-Versus-Host Disease--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):998-1001

College of Chinese Medicine , Shandong University of Traditional Chinese Medicine; Jinan 250011, Shandong Province, China,E-mail:

Acute intestinal graft-versus-host disease is a refractory disease which can affect implantation and become a threat to life in severe cases. Autophagy is an intracellular degradation pathway necessary for maintaining cellular energy homeostasis. In recent years, a large number of studies have found that it is closely related to the pathogenesis and process of acute intestinal graft-versus-host disease. Read More

View Article and Full-Text PDF

[Plasma MiR-181b and MiR-194 As Biomarkers for Acute Graft- Versus-Host Disease and Significance of Their Changes].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):957-962

Department of Hematology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, Fujian Province, China,E-mail:

Objective: To investigate the clinical correlation of expression level changes of miR-181b and miR-194 to the pathogenesis of acute graft-versus-host disease (aGVHD), and determine plasma miR-181b and miR-194 as the potential biomarkers for aGVHD.

Methods: The plasma samples were collected from 31 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at before HSCT, 15 days after HSCT and onset of aGVHD. The expression levels of miR-181b and miR-194 were detected by quantitative real-time PCR. Read More

View Article and Full-Text PDF

[Efficacy and Safety of PEG-rhG-CSF in HSC Mobilization in 71 Normal Healthy Donors for Allogeneic Hematopoietic Stem Cell Transplantation].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):951-956

Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.

Objective: To retrospectively analyze the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in hematopoietic stem cell mobilization in 71 normal healthy donors for allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods: From March 2018 to July 2019, 71 patients received allo-HSCT in The General Hospital of Western Theater Command were enrolled in the study, a single dose of PEG-rhG-CSF was injected subcutaneously at 12 mg to all the stem cell donors. After injection for 4 days, CD34 cell number were detected, stem cells were collected on day 4 or 5 according to the CD34 cell number. Read More

View Article and Full-Text PDF

[Clinical Analysis of CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):944-950

Department of Hematology, Guangzhou NO.1 People's Hospital, Guangzhou Medical University,Guangzhou 510180, Guangdong Province, China,E-mail:

Objective: To investigate the clinical characteristics and risk factors of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with severe aplastic anemia (SAA).

Methods: Clinical data from 270 SAA patients with allo-HSCT were retrospectively analyzed, including 108 sib congruence patients and 162 substitute donors (68 unrelated donor congruence patients and 94 related haploid patients). Different pretreatment schemes were selected for different transplantation modes. Read More

View Article and Full-Text PDF

[The Effect of γ-secretase Inhibitor Combined with BMSC on the aGVHD in Mice Model].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):937-943

Department of Hematology, Taian City Central Hospital, Shandong First Medical University, Taian 271000, Shandong Province, China,E-mail:

Objective: To establish the aGVHD mouse model,and investigate the regulatory effect and its mechanism of low-dose GSI combined with BMSC on aGVHD mice.

Methods: C57BL/6 (H-2b) and BALB/c (H-2d) were selected as donor and recipient of allogeneic transplantation to establish the aGVHD mouse model. BALB/c mice were randomly divided into 6 groups, which were the bone marrow cell infusion after irradiation (BM) group; the bone marrow cells + spleen cells after irradiation (BM+SC) group; the bone marrow cells + spleen cells + DMSO (BM+SC+DMSO) (transplant control) group; bone marrow cells + splenocytes +GSI after irradiation (BM+SC+GSI) group; bone marrow cells + spleen cells + bone marrow mesenchymal stromal infusion after irradiation cell (BM+SC+BMSC) group; bone marrow cells + spleen cells + bone marrow mesenchymal stromal cells +GSI infused after irradiation (BM+SC+BMSC+GSI) group. Read More

View Article and Full-Text PDF

[Kinetics of Infiltrating CD3 T Cells and Their Relationship with Target Organ Injury of Graft-Versus-Host Disease].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):931-936

Blood Diseases Institute, Xuzhou Medical University, Department of Hematology of The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China,E-mail:

Objective: To explore the kinetics of infiltrated T cell in murine acute graft-versus-host disease (aGVHD) target organs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its relationship with tissue pathological damage and aGVHD progress.

Methods: Male C57BL/6 (H-2K) mice at age of 8-10 weeks were selected as donors, from which splenic cells and bone marrow cells were isolated. And 10-12 weeks of BALB/c (H-2K) male mice which received 7. Read More

View Article and Full-Text PDF

[Efficacy and Relapse Prediction Model of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Acute Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):696-702

Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China,E-mail:

Objective: To observe the clinical efficacy of allogeneic peripheral blood stem cell transplantation(allo-HSCT) on the treatment of adult acute leukemia patients, moreover, to establish and evaluate a Logistic model to predict the risk of relapse in adult acute leukemia patients after allo-HSCT.

Methods: The clinical data of 145 adult acute leukemia patients treated by peripheral blood stem cell transplantation in the First Affiliated Hospital of Xi'an Jiaotong University from January 2010 to December 2019 was enrolled and analyzed retrospectively. Complications and survival of patients were observed. Read More

View Article and Full-Text PDF

Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and adenovirus.

Ther Adv Infect Dis 2021 Jan-Dec;8:20499361211018027. Epub 2021 May 24.

Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA, 01655, USA.

Human cytomegalovirus and Epstein-Barr virus have been recognized as potential drivers of morbidity and mortality of patients undergoing allogeneic stem cell transplantation for years. Specific protocols for monitoring, prophylaxis and pre-emptive therapy are in place in many transplant settings. In this review, we focus on the next three most frequent viruses, human herpesvirus-6, BK virus and adenovirus, causing reactivation and/or viremia after allogeneic transplant, which are increasingly detected in patients in the post-transplant period owing to emerging techniques of molecular biology, recipients' characteristics, treatment modalities used for conditioning and factors related donors or stem cell source. Read More

View Article and Full-Text PDF

Usefulness of capsule endoscopy in the diagnosis of gastrointestinal graft-versus-host disease.

Rev Gastroenterol Mex (Engl Ed) 2021 Jun 5. Epub 2021 Jun 5.

Servicio de Gastroenterología y Endoscopia Digestiva, Hospital Europeo Georges-Pompidou, Universidad de París, Paris, France.

View Article and Full-Text PDF

An Open-label, Single-arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.

Transplant Cell Ther 2021 Jun 5. Epub 2021 Jun 5.

Janssen Pharmaceutical K.K., Tokyo, Japan.

Background: Chronic graft-versus-host disease (cGVHD) is a serious complication after allogeneic stem cell transplantation. There are no well-established treatment options for cGVHD after primary steroid-based treatment. Ibrutinib showed clinical benefit with an acceptable safety profile in steroid-dependent/refractory cGVHD patients in a Phase 1b/2 study (PCYC-1129-CA, NCT02195869), with which it was approved in the United States for adult cGVHD patients after failure of ≥1 systemic treatments. Read More

View Article and Full-Text PDF

Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease.

J Clin Invest 2021 Jun;131(12)

Masonic Cancer Center and Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota, USA.

As a result of impressive increases in our knowledge of rodent and human immunology, the understanding of the pathophysiologic mechanisms underlying graft-versus-host disease (GVHD) has dramatically improved in the past 15 years. Despite improved knowledge, translation to clinical care has not proceeded rapidly, and results from experimental models have been inconsistent in their ability to predict the clinical utility of new therapeutic agents. In parallel, new tools in immunology have allowed in-depth analyses of the human system and have recently been applied in the field of clinical GVHD. Read More

View Article and Full-Text PDF